Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-resistant Prostate Cancer
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker.
- Trial name
- NCT07172126
- Testing
- TQB3201 tablets
- Where
- 3 sites in China
- Volunteers
- 291 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma
- Trial name
- NCT02499835
- Testing
- Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Wisconsin, Madison
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease, Radiation Nephropathy
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function over time.
- Conditions
- Kidney Disease, Radiation Nephropathy, Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Trial name
- KiRi (NCT06720532)
- Testing
- characterization of renal function., Handgrip strength test, Questionaires
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannah Schaefer
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
This phase I/Ib trial studies the side effects and best dose of Hu5F9-G4 (magrolimab) when given in combination with olaparib for the treatment of patients with breast or castrate-resistant prostate cancer that have spread from…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05807126
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Bone Metastatic Prostate Cancer
Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer
This is a prospective, open-label, single arm translational study of cabazitaxel in bone Castration Resistant metastatic Pancreatic Cancer (mCRPC) patients.
- Trial name
- CABA-BONE (NCT02512458)
- Testing
- Cabazitaxel
- Where
- 6 sites in Greece
- Volunteers
- 60 people
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 176 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment.
- Trial name
- NCT05999968
- Testing
- Abemaciclib, Darolutamide, LHRH agonist/antagonist
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer Metastatic
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- CYPIDES (NCT03436485)
- Testing
- ODM-208, Midazolam
- Where
- 20 sites in United States, Finland and 2 more
- Volunteers
- 204 people
- Sponsor
- Orion Corporation, Orion Pharma
Prostate Cancer
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
PSMA ADC 2301EXT is an open-label study to further assess the anti-tumor activity as measured by radiographic imaging and biomarkers, safety and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA…
- Trial name
- NCT02020135
- Testing
- PSMA ADC
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to…
- Conditions
- Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance
- Trial name
- NCT05848011
- Testing
- lorigerlimab, docetaxel, Prednisone
- Where
- 61 sites in United States, Australia and 8 more
- Volunteers
- 154 people
- Sponsor
- MacroGenics
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
This is a PhaseI, open-label study, Dose-Escalation Study, where tolerated doses will be escalated to the next doses with the safety, tolerability, and PK being evaluated in metastatic castration-resistant prostate cancer (mCRPC)…
- Trial name
- NCT03074032
- Testing
- ONC1-0013B
- Where
- 2 sites in Russia
- Volunteers
- 17 people
- Sponsor
- Avionco LLC
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Prostatic Neoplasms
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
- Trial name
- NCT05022849
- Testing
- JNJ-75229414, Bridging Therapy
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib.
- Trial name
- KHLAD (NCT00953576)
- Testing
- ketoconazole, hydrocortisone, dutasteride
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer Non-Metastatic, Castration-Resistant
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
- Trial name
- ARAMIS (NCT02200614)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 404 sites in United States, Argentina and 34 more
- Volunteers
- 1,509 people
- Sponsor
- Bayer
Advanced Solid Tumor, RAF Mutation
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation
- Trial name
- NCT06287463
- Testing
- DCC-3084
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
BKM120 in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K).
- Trial name
- NCT01385293
- Testing
- BKM120
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew J. Armstrong, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.